Last reviewed · How we verify
gonadotropin releasing hormone-agonist
The gonadotropin releasing hormone-agonist, developed by Alexandria University, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of clear competitive positioning and trial results, which may impact market adoption and future revenue growth.
At a glance
| Generic name | gonadotropin releasing hormone-agonist |
|---|---|
| Also known as | triptorelin 0.1 mg |
| Sponsor | Alexandria University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- Body Composition Assessment in Transgender Population.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gonadotropin releasing hormone-agonist CI brief — competitive landscape report
- gonadotropin releasing hormone-agonist updates RSS · CI watch RSS
- Alexandria University portfolio CI